Author

N. Daver

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1

Frequent Co-Authors

K. Takahashi· 3 shared G. Garcia-Manero· 2 shared H. A. Abbas· 2 shared J. Zhang· 2 shared L. Little· 2 shared P. A. Futreal· 2 shared P. K. Reville· 2 shared A. C. Jain· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. Takahashi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Clonal evolution of hematopoietic stem cells after cancer chemotherapy

H. Uryu, K. Saeki, H. Haeno, C. D. Kapadia, K. Furudate, J. Nangalia, M. S. Chapman, L. Zhao, J. I. Hsu, C. Zhao, S. Chen, T. Tanaka, Z. Li, H. Yang, C. DiNardo, , K. Takahashi

This study examines how chemotherapy affects clonal diversity and mutation patterns in hematopoietic stem cells, finding that melphalan increases mutational burden and promotes clonal aging, potentially leading to therapy-related myeloid neoplasms.

bioRxiv · May 23, 2024Cancer Biology

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins, M. Hentemann, B. Cuglievan, C. P. Mill, C. E. Birdwell, K. Das, J. A. Davis, H. Hou, A. C. Jain, A. Malovannaya, T. M. Kadia, N. Daver, K. Sasaki, , K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

bioRxiv · Sep 28, 2023Cancer Biology

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

A. G. X. Zeng, S. Bansal, L. Jin, A. Mitchell, W. C. Chen, H. A. Abbas, M. Chan-Seng-Yue, V. Voisin, P. van Galen, A. Tierens, M. Cheok, C. Preudhomme, H. Dombret, N. Daver, P. A. Futreal, , J. E. Dick

This study identifies a cellular hierarchy framework in AML that links disease heterogeneity with drug response and develops a 7-gene biomarker predictive of drug sensitivity.

bioRxiv · Jan 25, 2022Cancer Biology

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

H. A. Abbas, D. Hao, K. Tomczak, P. Baroodia, J. Im, P. K. Reville, Z. Alaniz, W. Wang, R. Wang, F. Wang, G. Al-Atrash, K. Takahashi, J. Ning, M. Ding, J. Matthews, , A. Futreal

This study analyzes single-cell RNA and TCR profiles from AML patients before and after PD-1 blockade therapy to identify factors influencing response and resistance.

bioRxiv · Sep 3, 2020Cancer Biology